These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 9481610)

  • 1. Cardiovascular care with the new T-type calcium channel antagonist: possible role of attendant sympathetic nervous system inhibition.
    Bühler FR
    J Hypertens Suppl; 1997 Dec; 15(5):S3-7. PubMed ID: 9481610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade.
    Noll G; Lüscher TF
    Cardiology; 1998; 89 Suppl 1():10-5. PubMed ID: 9570424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mibefradil: a selective T-type calcium antagonist.
    Massie BM
    Am J Cardiol; 1997 Nov; 80(9A):23I-32I. PubMed ID: 9375939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mibefradil: a new class of calcium-channel antagonists.
    Billups SJ; Carter BL
    Ann Pharmacother; 1998 Jun; 32(6):659-71. PubMed ID: 9640486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium antagonists and sympathetic nerve activation: are there differences between classes?
    Noll G; Wenzel RR; Shaw S; Lüscher TF
    J Hypertens Suppl; 1998 Jan; 16(1):S17-24. PubMed ID: 9534092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term calcium antagonist treatment of human hypertension with mibefradil or amlodipine increases sympathetic nerve activity.
    Lindqvist M; Kahan T; Melcher A; Ekholm M; Hjemdahl P
    J Hypertens; 2007 Jan; 25(1):169-75. PubMed ID: 17143189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium ions, drug action and the heart--with special reference to calcium antagonist drugs.
    Opie LH
    Pharmacol Ther; 1984; 25(3):271-95. PubMed ID: 6151199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications.
    Opie LH
    Cardiovasc Drugs Ther; 1988 Mar; 1(6):625-56. PubMed ID: 3154329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential properties of mibefradil in hypertension and angina.
    Kobrin I
    J Hypertens Suppl; 1997 Dec; 15(5):S33-40. PubMed ID: 9481614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of calcium antagonists in cardiovascular therapy.
    Dargie H; Rowland E; Krikler D
    Br Heart J; 1981 Jul; 46(1):8-16. PubMed ID: 7023517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological basis for the therapeutic applications of slow-channel blocking drugs.
    Singh BN
    Angiology; 1982 Aug; 33(8):492-515. PubMed ID: 7051905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of calcium channel antagonists for cardiovascular disease.
    Yedinak KC
    Am Pharm; 1993 Aug; NS33(8):49-64; quiz 64-6. PubMed ID: 8213473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases.
    Lüscher TF; Wenzel RR; Moreau P; Takase H
    Cardiovasc Drugs Ther; 1995 Aug; 9 Suppl 3():509-23. PubMed ID: 8562468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of calcium antagonists in ischaemic heart disease.
    Pepine CJ
    Eur Heart J; 1995 Aug; 16 Suppl H():19-24. PubMed ID: 8846801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the calcium channel blockers, diltiazem and Ro 40-5967, on systemic haemodynamics and plasma noradrenaline levels in conscious dogs with pacing-induced heart failure.
    Su J; Renaud N; Carayon A; Crozatier B; Hittinger L
    Br J Pharmacol; 1994 Oct; 113(2):395-402. PubMed ID: 7834190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mibefradil, a pharmacologically distinct calcium antagonist.
    Ernst ME; Kelly MW
    Pharmacotherapy; 1998; 18(3):463-85. PubMed ID: 9620098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcium antagonist treatment, sympathetic activity and platelet function.
    Hjemdahl P; Wallén NH
    Eur Heart J; 1997 Jan; 18 Suppl A():A36-50. PubMed ID: 9049538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hypertension with calcium channel blockers: European data.
    Klein WW
    Am J Med; 1984 Oct; 77(4A):143-6. PubMed ID: 6385698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologic and pathophysiologic relevance of T-type calcium-ion channels: potential indications for T-type calcium antagonists.
    Hermsmeyer K; Mishra S; Miyagawa K; Minshall R
    Clin Ther; 1997; 19 Suppl A():18-26. PubMed ID: 9385502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Calcium antagonists in the treatment of heart failure. Re-evaluation of therapeutic strategies].
    Gattis W; O'Connor CM
    Drugs; 2000; 59 Spec No 2():17-24. PubMed ID: 11002855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.